Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Chemclin Diagnostics CoSHSE:688468 -2.97%72 Days Payable is 63.43 as of Mar. 2026, which is 27% below its 10-year median of 87.39. GuruFocus rates SHSE:688468 with a GF Score™ of 72/100 and a GF Value™ of ¥5.75 (Fairly Valued). The stock has 6 warning signs investors should review. Among 190 Medical Diagnostics & Research companies, Chemclin Diagnostics Co ranks better than 60% on this metric.
The historical rank and industry rank for Chemclin Diagnostics Co's Days Payable or its related term are showing as below:
SHSE:688468'
s Days Payable Range Over the Past 10 Years
Min: 47.14 Med: 87.39 Max: 262.78
Current: 87.55
During the past 9 years, Chemclin Diagnostics Co's highest Days Payable was 262.78. The lowest was 47.14. And the median was 87.39.
SHSE:688468's Days Payable is ranked better than 60% of 190
companies
in the Medical Diagnostics & Research industry
Industry Median: 64.64
vs SHSE:688468: 87.55
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688468 vs TMO, DHR, IDXX: Days Payable Comparison
For the Diagnostics & Research subindustry, Chemclin Diagnostics Co's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Chemclin Diagnostics Co Days Payable vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Chemclin Diagnostics Co's Days Payable distribution charts can be found below:
* The bar in red indicates where Chemclin Diagnostics Co's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Chemclin Diagnostics Co's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Chemclin Diagnostics Co (SHSE:688468) has a Days Payable of 63.43 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemclin Diagnostics Co and its competitors. This is 27% below median its historical median of 87.39. Over the past decade, Chemclin Diagnostics Co's Days Payable has ranged from 47.14 to 262.78. According to the industry distribution chart, Chemclin Diagnostics Co ranks #76 out of 190 companies in the Medical Diagnostics & Research industry, placing it in the top 40%.
Is Chemclin Diagnostics Co's Days Payable too high?
Chemclin Diagnostics Co's current Days Payable of 63.43 is 27% below median its 10-year median of 87.39. Over the past 10 years, this metric has ranged from a low of 47.14 to a high of 262.78. The Medical Diagnostics & Research industry median Days Payable is 64.64. Chemclin Diagnostics Co's value of 63.43 is 1.9% below this industry median. Based on the distribution chart, Chemclin Diagnostics Co ranks #76 out of 190 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Chemclin Diagnostics Co has a GF Score™ of 72/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Chemclin Diagnostics Co's Days Payable compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Chemclin Diagnostics Co ranks #76 out of 190 companies for Days Payable. This puts Chemclin Diagnostics Co in the upper half of its industry. The industry median Days Payable is 64.64. Chemclin Diagnostics Co's value of 63.43 is 1.9% below this benchmark. Historically, Chemclin Diagnostics Co's own Days Payable has ranged from 47.14 to 262.78 over the past decade. While the company's 10-year median is 87.39 vs. the industry median of 64.64, Chemclin Diagnostics Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Medical Diagnostics & Research company?
The median Days Payable among Medical Diagnostics & Research companies is 64.64, based on 190 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Chemclin Diagnostics Co's current Days Payable of 63.43 is 1.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Chemclin Diagnostics Co and its competitors. For the Medical Diagnostics & Research industry, the median Days Payable is 64.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Chemclin Diagnostics Co's current Days Payable is 63.43, which is 27% below median its own 10-year median of 87.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Chemclin Diagnostics Co stock overvalued right now?
Based on GuruFocus' analysis, Chemclin Diagnostics Co (SHSE:688468) is currently considered Fairly Valued. The stock's GF Value™ is ¥5.75, compared to a current price of ¥5.55 — trading 3.5% below its estimated fair value. The current Days Payable is 63.43, which is 27% below median its 10-year median of 87.39 and 1.9% below the Medical Diagnostics & Research industry median of 64.64. Chemclin Diagnostics Co's overall GF Score™ is 72/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Chemclin Diagnostics Co (SHSE:688468), the current Days Payable is 63.43 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Chemclin Diagnostics Co (SHSE:688468) Overvalued in 2026?
Based on GuruFocus' analysis, Chemclin Diagnostics Co stock appears to be undervalued.
The current stock price of ¥5.55 is trading 3.5% below its estimated GF Value™ of ¥5.75.
GuruFocus considers Chemclin Diagnostics Co to be Fairly Valued.
Key valuation signals for SHSE:688468:
Days Payable: 63.43 (27% below median its 10-year median of 87.39)
GF Value™: ¥5.75 vs. price of ¥5.55 (3.5% below fair value)
Industry Position: 1.9% below the Medical Diagnostics & Research median (#76 of 190)
No single metric tells the full story. See the SHSE:688468 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Chemclin Diagnostics Co Ltd is engaged in the development, production and sales of clinical immunochemiluminescence diagnostic testing reagents and instruments.
72GF Score
Get the complete analysis for SHSE:688468
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688468 has been successfully added to your 
